Related references
Note: Only part of the references are listed.A phase I study of LDE225 in combination with docetaxel in patients with triple negative (TN) advanced breast cancer (ABC): GEICAM/2012-12 (EDALINE study)
Miguel Martin et al.
CANCER RESEARCH (2015)
Inhibition of the hedgehog pathway with sonidegib (LDE225) in advanced basal cell carcinoma
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2015)
Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicentre, randomised, double-blind phase 2 trial
Michael R. Migden et al.
LANCET ONCOLOGY (2015)
A Five-Gene Hedgehog Signature Developed as a Patient Preselection Tool for Hedgehog Inhibitor Therapy in Medulloblastoma
Yaping Shou et al.
CLINICAL CANCER RESEARCH (2015)
Inhibition of Hedgehog signalling by NVP-LDE225 (Erismodegib) interferes with growth and invasion of human renal cell carcinoma cells
C. D'Amato et al.
BRITISH JOURNAL OF CANCER (2014)
Absorption, distribution, metabolism, and excretion (ADME) of 14C-sonidegib (LDE225) in healthy volunteers
Markus Zollinger et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2014)
Abstract 3193: NPV-LDE-225 (Erismodegib) inhibits human prostate cancer stem cell growth in NOD/SCID IL2Rγ null mice by regulating Bmi-1 and microRNA-128.
Rajesh Nanta et al.
CANCER RESEARCH (2014)
A Phase I, Multicenter, Open-Label, First-in-Human, Dose-Escalation Study of the Oral Smoothened Inhibitor Sonidegib (LDE225) in Patients with Advanced Solid Tumors
Jordi Rodon et al.
CLINICAL CANCER RESEARCH (2014)
Noninvasive monitoring of basal cell carcinomas treated with systemic hedgehog inhibitors: Pseudocysts as a sign of tumor regression
Tanja Maier et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2014)
Structure of the human smoothened receptor bound to an antitumour agent
Chong Wang et al.
NATURE (2013)
NPV-LDE-225 (Erismodegib) inhibits epithelial mesenchymal transition and self-renewal of glioblastoma initiating cells by regulating miR-21, miR-128, and miR-200
Junsheng Fu et al.
NEURO-ONCOLOGY (2013)
NVP-LDE225, a potent and Selective SMOOTHENED Antagonist Reduces Melanoma Growth In Vitro and In Vivo
Ahmad Jalili et al.
PLOS ONE (2013)
Hedgehog Signaling Inhibition Blocks Growth of Resistant Tumors through Effects on Tumor Microenvironment
Emanuela Heller et al.
CANCER RESEARCH (2012)
Smoothened Antagonists Reverse Taxane Resistance in Ovarian Cancer
Adam D. Steg et al.
MOLECULAR CANCER THERAPEUTICS (2012)
Hedgehog Inhibition With the Orally Bioavailable Smo Antagonist LDE225 Represses Tumor Growth and Prolongs Survival in a Transgenic Mouse Model of Islet Cell Neoplasms
Volker Fendrich et al.
ANNALS OF SURGERY (2011)
Topical Treatment of Basal Cell Carcinomas in Nevoid Basal Cell Carcinoma Syndrome with a Smoothened Inhibitor
Hans Skvara et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2011)
Basal cell carcinomas: attack of the hedgehog
Ervin H. Epstein
NATURE REVIEWS CANCER (2008)
Share Paper
